1. A 49-year-old woman has been stable on amitriptyline 75 mg nightly for depression and chronic neuropathic pain, with a plasma level of 168 ng/mL (combined amitriptyline plus nortriptyline; therapeutic target 100--300 ng/mL) for eight months. Her psychiatrist adds fluoxetine 20 mg daily for residual depressive symptoms. Seven weeks later she presents with confusion, tachycardia at 116 bpm, dry mouth, and constipation. A repeat combined plasma level is 412 ng/mL. Which of the following is the most appropriate immediate management step, and what is the correct mechanistic explanation for this clinical deterioration?
A) Increase the amitriptyline dose to 100 mg nightly to overcome the apparent pharmacodynamic tolerance that has developed after eight months of treatment, and add a laxative for the constipation; the elevated plasma level reflects assay interference from fluoxetine cross-reactivity with the amitriptyline immunoassay rather than true drug accumulation
B) Discontinue fluoxetine immediately and start a different antidepressant with no CYP2D6 inhibitory activity; switch amitriptyline to a non-TCA agent because this interaction demonstrates that the patient cannot safely receive any TCA; the elevated level reflects fluoxetine's direct displacement of amitriptyline from plasma protein binding sites
C) Reduce or hold the amitriptyline dose and recheck the combined plasma level at steady state after approximately two weeks; the deterioration reflects fluoxetine's potent CYP2D6 inhibition reducing the metabolic clearance of both amitriptyline and its active metabolite nortriptyline, raising the combined plasma concentration to a level that produces anticholinergic toxicity; the amitriptyline dose should be reduced rather than the regimen abandoned, as the combination can be managed safely with appropriate dose adjustment and level monitoring
D) Continue the current regimen and recheck the plasma level in four weeks; the elevated level and symptoms are expected during the first eight weeks of any new antidepressant combination and will resolve spontaneously as the patient develops pharmacodynamic tolerance to the anticholinergic effects of amitriptyline at the new steady-state concentration
E) Discontinue amitriptyline entirely and transition to a selective serotonin reuptake inhibitor (SSRI) monotherapy; the elevated combined level reflects irreversible CYP2D6 inactivation by fluoxetine that will persist indefinitely, making safe re-dosing of any TCA impossible while fluoxetine or its metabolites remain in the body
ANSWER: C
Rationale:
Option C is correct. Fluoxetine is a potent CYP2D6 inhibitor, and CYP2D6 is the principal enzyme responsible for clearance of both amitriptyline and its active secondary amine metabolite nortriptyline. Addition of fluoxetine to a stable amitriptyline regimen reduces the clearance of both compounds, raising the combined plasma concentration from 168 to 412 ng/mL -- well above the therapeutic target. The resulting supratherapeutic exposure produces the anticholinergic toxicity syndrome observed: confusion from central muscarinic blockade, tachycardia from vagal tone suppression at the sinoatrial node, dry mouth from salivary gland inhibition, and constipation from gut motility inhibition. The correct immediate step is to reduce or hold the amitriptyline dose and recheck the combined level at a new steady state approximately two weeks after the dose change. This interaction is predictable, reversible, and manageable with dose adjustment -- it does not require abandoning the TCA. Plasma level monitoring is precisely the tool designed to manage this scenario.
Option A: Option A is incorrect. Increasing the amitriptyline dose would worsen the toxicity, not address it. Pharmacodynamic tolerance does not explain a threefold rise in plasma concentration. Fluoxetine does not produce immunoassay cross-reactivity that falsely elevates TCA measurements.
Option B: Option B is incorrect. While discontinuing fluoxetine is a reasonable option, the rationale that this interaction proves the patient cannot receive any TCA is incorrect. The interaction is pharmacokinetic -- CYP2D6 inhibition -- and resolves with dose adjustment or removal of the inhibitor. Protein displacement is not the mechanism.
Option D: Option D is incorrect. Continuing the current regimen without dose adjustment in a patient with a level of 412 ng/mL and symptomatic anticholinergic toxicity is not appropriate. Anticholinergic toxicity does not resolve through tolerance while supratherapeutic drug levels persist.
Option E: Option E is incorrect. Fluoxetine and its active metabolite norfluoxetine inhibit CYP2D6 reversibly, not irreversibly through enzyme inactivation in the mechanism-based sense that would permanently abolish CYP2D6 activity. Once fluoxetine and norfluoxetine are cleared (over approximately five weeks), CYP2D6 activity returns to baseline.
2. An 81-year-old man with major depressive disorder and chronic low back pain was started on imipramine 50 mg nightly three weeks ago by his primary care physician. He presents to the emergency department with inability to void for 18 hours, confusion and disorientation, a heart rate of 108 bpm, dry flushed skin, and dilated pupils. Bladder scan shows 620 mL of retained urine. His medication list includes lisinopril, atorvastatin, and the recently started imipramine. Which of the following represents the most appropriate management, and what receptor mechanism explains why this patient is particularly vulnerable to this complication?
A) Perform immediate urological consultation for cystoscopy to rule out prostatic obstruction as the primary cause; add bethanechol (a direct muscarinic agonist) to overcome the imipramine-induced bladder inhibition while continuing imipramine, as the antidepressant benefit outweighs the risk in a patient with established depression
B) Insert a urinary catheter for immediate relief, administer intravenous physostigmine to reverse the central and peripheral anticholinergic syndrome, and continue imipramine at a reduced dose of 25 mg nightly with close monitoring; this patient is vulnerable because of age-related reduction in renal clearance of imipramine
C) Administer intravenous fluids to improve renal perfusion and stimulate voiding, add tamsulosin (an alpha-1 blocker) to relax urethral smooth muscle, and continue imipramine; this patient is vulnerable because imipramine's alpha-1 adrenergic blockade selectively targets the urethral sphincter in elderly males
D) Insert a urinary catheter for immediate bladder decompression, administer sodium bicarbonate intravenously to alkalinize urine and enhance imipramine excretion, and restart imipramine at 25 mg after the urinary retention resolves; this patient is vulnerable because of age-related reduction in CYP2D6 activity that causes imipramine accumulation
E) Discontinue imipramine, insert a urinary catheter for immediate bladder decompression, and provide supportive care for the anticholinergic syndrome; imipramine's muscarinic receptor blockade inhibits detrusor contractility, and this patient is particularly vulnerable because elderly men frequently have pre-existing bladder outlet obstruction from benign prostatic hyperplasia, and age-related reduction in CNS cholinergic reserve makes central anticholinergic toxicity (confusion, delirium) more likely at any given plasma concentration
ANSWER: E
Rationale:
Option E is correct. This patient presents with the full peripheral and central anticholinergic syndrome from imipramine: urinary retention (muscarinic blockade of the detrusor muscle), confusion and disorientation (central muscarinic blockade), tachycardia (muscarinic blockade at the sinoatrial node), dry flushed skin (anhidrosis and cutaneous vasodilation), and dilated pupils (ciliary muscle and iris sphincter inhibition). Imipramine is a tertiary amine TCA with high muscarinic receptor binding potency. The correct management is to discontinue imipramine immediately -- continuing the causative drug at a reduced dose is not appropriate when the patient has acute urinary retention and delirium -- and to insert a urinary catheter for immediate bladder decompression, as 620 mL of retained urine risks bladder injury. Two age-related factors amplify his vulnerability: first, elderly men commonly have pre-existing lower urinary tract obstruction from benign prostatic hyperplasia, meaning even modest muscarinic blockade of the detrusor can produce complete retention; second, age-related progressive loss of cholinergic neurons in cortical pathways reduces CNS cholinergic reserve, making older patients more susceptible to delirium from anticholinergic drug burden at plasma concentrations tolerated by younger patients.
Option A: Option A is incorrect. Bethanechol (a direct muscarinic agonist) can transiently overcome bladder inhibition but does not address the systemic anticholinergic syndrome including delirium, and continuing imipramine perpetuates the cause. The primary management is to remove the offending drug.
Option B: Option B is incorrect. Physostigmine is contraindicated when there is cardiac sodium channel toxicity (QRS widening), and while not indicated here for that reason, intravenous physostigmine carries risk of bradycardia and is not the standard management for this presentation. Continuing imipramine at a reduced dose is inappropriate. Age-related reduction in renal clearance is not the primary vulnerability explanation -- the anticholinergic receptor pharmacology is.
Option C: Option C is incorrect. Tamsulosin relaxes urethral smooth muscle via alpha-1 blockade and may be adjunctively useful, but it does not address the underlying anticholinergic mechanism and does not treat the delirium. Imipramine must be discontinued.
Option D: Option D is incorrect. Sodium bicarbonate enhances imipramine excretion only negligibly given the enormous volume of distribution; urinary alkalinization is not a clinically meaningful elimination strategy for TCAs.
3. A 23-year-old woman is brought to the emergency department 75 minutes after ingesting an unknown quantity of her roommate's doxepin. She is drowsy but responsive to voice with a GCS of 13. Vital signs: heart rate 118 bpm, blood pressure 96/58 mmHg. Initial ECG shows a QRS of 88 ms. She is placed on continuous cardiac monitoring and intravenous access is established. Thirty minutes later she is more somnolent (GCS 10) and a repeat ECG shows QRS of 106 ms with a rightward terminal axis shift and a prominent R wave in lead aVR. The emergency physician prepares to act. Which of the following represents the correct next step and the correct target for therapy?
A) Administer intravenous sodium bicarbonate as bolus doses of 1 to 2 mEq/kg now, targeting blood pH 7.45 to 7.55 and monitoring for QRS narrowing toward baseline; the QRS of 106 ms has crossed the 100 ms seizure-risk threshold and the prominent aVR R wave provides additional evidence of significant sodium channel blockade, both of which indicate bicarbonate therapy without waiting for arrhythmia to develop
B) Continue observation without pharmacological intervention; sodium bicarbonate is indicated only after ventricular arrhythmia develops, as premature alkalinization carries the risk of overshooting to pH greater than 7.55 and precipitating hypocalcemic tetany; the QRS of 106 ms does not yet warrant treatment because the arrhythmia threshold is QRS greater than 160 ms
C) Administer intravenous phenytoin 20 mg/kg to stabilize cardiac sodium channels before arrhythmia develops; the QRS widening indicates significant sodium channel blockade and phenytoin's sodium channel-stabilizing properties will reverse the conduction defect; sodium bicarbonate should be held until phenytoin levels are established
D) Administer intravenous physostigmine to reverse the central nervous system depression and the tachycardia, both of which reflect TCA-induced anticholinergic toxicity; the QRS widening is a secondary phenomenon that will improve once the underlying anticholinergic syndrome is treated; sodium bicarbonate should be reserved for patients who are unresponsive to physostigmine
E) Administer activated charcoal orally to reduce further doxepin absorption; sodium bicarbonate is not indicated at a QRS of 106 ms because the established threshold for bicarbonate is QRS greater than 120 ms; the rightward axis shift on ECG is a normal variant and does not indicate toxicity at this stage of the overdose
ANSWER: A
Rationale:
Option A is correct. This patient's ECG evolution -- QRS widening from 88 to 106 ms with a rightward terminal axis shift and prominent R wave in lead aVR -- indicates progressive cardiac sodium channel blockade from doxepin. Two findings independently support immediate sodium bicarbonate therapy: first, a QRS duration exceeding 100 milliseconds is a well-established predictor of seizure risk and is the threshold for initiating bicarbonate therapy; second, an R-wave amplitude greater than 3 mm in lead aVR independently predicts both seizures and ventricular arrhythmias. Sodium bicarbonate should be administered as intravenous bolus doses of 1 to 2 mEq/kg, with the target blood pH of 7.45 to 7.55 and serial ECG monitoring for QRS narrowing. The goal is to reverse sodium channel blockade before arrhythmia develops -- not to wait for arrhythmia as the trigger for treatment.
Option B: Option B is incorrect. Waiting for ventricular arrhythmia to develop before giving bicarbonate is an incorrect management approach that risks irreversible hemodynamic deterioration. The 100 ms QRS threshold and the aVR finding are both established treatment triggers. The target pH of 7.45 to 7.55 is the intended goal of therapy, not an overshoot.
Option C: Option C is incorrect. Phenytoin is specifically contraindicated in TCA overdose. Its sodium channel-blocking mechanism is additive with TCA-induced cardiac sodium channel blockade and can worsen QRS prolongation and precipitate ventricular arrhythmia rather than treat it.
Option D: Option D is incorrect. Physostigmine is contraindicated in TCA overdose with cardiac sodium channel toxicity. Its cholinesterase inhibition increases vagal tone at the sinoatrial node and can cause bradycardia or asystole in the setting of impaired cardiac conduction. QRS widening is not secondary to anticholinergic syndrome -- it reflects direct sodium channel blockade.
Option E: Option E is incorrect. Activated charcoal within one hour of ingestion with an unprotected airway is hazardous; this patient's decreasing level of consciousness (GCS 10) makes aspiration risk prohibitive without airway protection. The bicarbonate threshold is QRS greater than 100 ms, not 120 ms. The rightward axis shift in the context of TCA overdose is a recognized toxicity finding, not a normal variant.
4. A 52-year-old woman on phenelzine 45 mg daily for treatment-resistant depression calls her psychiatrist's office reporting a severe, sudden-onset pounding headache that began 30 minutes ago. She is diaphoretic and nauseated. The nurse who takes the call learns that the patient attended a dinner party earlier that evening and consumed aged Camembert cheese, cured salami, and a glass of red wine. Her blood pressure measured at home is 228/124 mmHg. Which of the following is the most appropriate immediate response and correctly identifies the mechanism of this presentation?
A) Advise the patient to take an oral dose of her as-needed lorazepam to reduce sympathetic activation, lie down in a quiet room, and call back in 30 minutes if symptoms persist; the mechanism is serotonin syndrome triggered by the tryptophan content of aged cheeses interacting with phenelzine's MAO-A inhibition to produce serotonin excess
B) Instruct the patient to call emergency services (911) immediately for transport to the nearest emergency department, as this presentation is consistent with a tyramine-induced hypertensive crisis -- dietary tyramine bypassed MAO-A first-pass extraction, entered adrenergic nerve terminals via the norepinephrine transporter, displaced stored norepinephrine in massive quantities, and produced acute severe hypertension; intracerebral hemorrhage is the most feared complication and this is a medical emergency requiring immediate evaluation and parenteral antihypertensive therapy
C) Advise the patient to take a sublingual nitroglycerin tablet from her cardiac medication supply and recheck her blood pressure in 15 minutes; if the blood pressure does not fall below 180 mmHg systolic within 30 minutes, she should present to an urgent care clinic; the mechanism is phenelzine-induced impairment of nitric oxide metabolism producing vasospasm
D) Instruct the patient to take an additional dose of phenelzine to counter the norepinephrine excess through upregulation of presynaptic MAO-A, which will catabolize the excess norepinephrine and lower the blood pressure; the mechanism is rebound sympathetic activation from dietary tyramine competing with phenelzine for MAO-A binding sites
E) Advise the patient that this is a predictable and self-limiting interaction that will resolve within two to three hours as tyramine is metabolized by MAO-B (which phenelzine does not inhibit); instruct her to rest, avoid further tyramine-containing foods, and present to her psychiatrist's office the following morning for a blood pressure check
ANSWER: B
Rationale:
Option B is correct. This is a medical emergency. The clinical constellation -- sudden severe pounding headache, diaphoresis, nausea, and blood pressure of 228/124 mmHg in a patient on phenelzine who consumed aged cheese, cured meat, and red wine -- is the classic presentation of a tyramine-induced hypertensive crisis. Phenelzine irreversibly inhibits MAO-A in the intestinal mucosa and liver, abolishing first-pass tyramine extraction. Dietary tyramine from the aged Camembert and cured salami entered the systemic circulation intact, was transported into peripheral adrenergic nerve terminals by the norepinephrine transporter (NET), displaced stored norepinephrine in massive quantities, and produced acute severe hypertension through alpha-1 receptor activation at peripheral resistance vessels. A blood pressure of 228/124 mmHg carries immediate risk of intracerebral hemorrhage, hypertensive encephalopathy, and aortic dissection. The patient must go to an emergency department immediately for parenteral antihypertensive therapy -- phentolamine (alpha-adrenergic blocker) is the classic agent; labetalol and nicardipine are also used. Phone reassurance with watchful waiting is inappropriate at this blood pressure.
Option A: Option A is incorrect. Lorazepam does not meaningfully lower blood pressure in a hypertensive crisis and has no pharmacological effect on the norepinephrine excess driving this presentation. This is not serotonin syndrome -- the mechanism is noradrenergic, not serotonergic.
Option C: Option C is incorrect. This presentation requires emergency department evaluation and parenteral therapy, not sublingual nitroglycerin and a 30-minute wait. Nitroglycerin is a venodilator with modest arterial effects and is not appropriate monotherapy for a hypertensive crisis at this blood pressure. The mechanism described is fabricated.
Option D: Option D is incorrect. Additional phenelzine would not counter the norepinephrine excess -- MAO-A is already irreversibly inhibited, and norepinephrine is not catabolized by MAO-A once it has been released into the synapse. This option describes a biologically implausible mechanism.
Option E: Option E is incorrect. This is not a self-limiting interaction. The tyramine has already displaced norepinephrine from nerve terminals; the crisis is underway. MAO-B cannot compensate for absent MAO-A in metabolizing the circulating tyramine or the released norepinephrine. A blood pressure of 228/124 mmHg is immediately life-threatening.
5. A 41-year-old woman with treatment-resistant atypical depression has failed three SSRI trials and two SNRI trials. Her psychiatrist decides to transition her to phenelzine. She has been taking fluoxetine 40 mg daily for the past 11 months. The psychiatrist instructs her to stop fluoxetine today and schedules a follow-up appointment in two weeks to start phenelzine. A clinical pharmacist reviewing the plan contacts the psychiatrist to flag a safety concern. Which of the following correctly identifies the pharmacist's concern and the correct washout interval, with the pharmacokinetic explanation?
A) The pharmacist's concern is that two weeks is too long to wait; fluoxetine has a plasma half-life of only 24 to 36 hours and is fully cleared within five days; the patient can safely start phenelzine after seven days, and waiting two weeks unnecessarily prolongs the patient's exposure to undertreated depression
B) The pharmacist's concern is that phenelzine cannot be used after fluoxetine because fluoxetine irreversibly inactivates MAO-A through a mechanism-based inhibition, and patients previously treated with fluoxetine have permanently reduced MAO-A capacity regardless of washout duration; a different antidepressant class must be chosen
C) The pharmacist's concern is that two weeks is insufficient; the correct washout is four weeks because fluoxetine's active metabolite norfluoxetine has a half-life of approximately seven days, and three half-lives (21 days, rounded to four weeks for clinical safety) must elapse before MAO inhibition is safe
D) The pharmacist's concern is that two weeks is insufficient; fluoxetine is metabolized to norfluoxetine, an active SERT inhibitor with a plasma half-life of one to two weeks; five half-lives of norfluoxetine -- approximately five weeks -- must elapse before both fluoxetine and norfluoxetine are cleared to sub-pharmacological concentrations; starting phenelzine at two weeks risks serotonin syndrome from combined SERT inhibition by residual norfluoxetine and MAO-A inhibition by phenelzine
E) The pharmacist's concern is that the two-week washout is appropriate for fluoxetine itself but the patient must also discontinue atorvastatin for two weeks before starting phenelzine because statins are potent CYP2D6 inhibitors that impair phenelzine metabolism and can produce phenelzine toxicity at standard doses
ANSWER: D
Rationale:
Option D is correct. The pharmacist has identified a potentially fatal prescribing error. Two weeks is an insufficient washout after fluoxetine before starting an irreversible MAOI. Fluoxetine is metabolized to norfluoxetine, a pharmacologically active SERT inhibitor with a plasma half-life of one to two weeks -- far longer than fluoxetine's own half-life of one to four days. At five half-lives of norfluoxetine (approximately five weeks), both parent drug and active metabolite have been cleared to sub-pharmacological concentrations. Starting phenelzine at two weeks means norfluoxetine is still present at clinically significant concentrations, still inhibiting SERT. The combination of residual SERT inhibition from norfluoxetine and MAO-A inhibition from phenelzine simultaneously prevents serotonin reuptake and serotonin catabolism, producing massive serotonin accumulation and serotonin syndrome -- a potentially fatal reaction. The five-week washout for fluoxetine before any irreversible MAOI is one of the most clinically important pharmacokinetic rules in antidepressant prescribing. For most other SSRIs (sertraline, citalopram, escitalopram, paroxetine) the washout is approximately one to two weeks, reflecting their shorter half-lives and absence of a long-lived active metabolite.
Option A: Option A is incorrect. The statement that fluoxetine has a half-life of 24 to 36 hours and is cleared in five days ignores norfluoxetine entirely. This is precisely the error that leads to dangerous premature MAOI initiation.
Option B: Option B is incorrect. Fluoxetine does not irreversibly inactivate MAO-A. Its CYP2D6 inhibitory properties are reversible, and it has no pharmacological interaction with MAO-A. The claim that prior fluoxetine use permanently reduces MAO-A capacity is biologically implausible.
Option C: Option C is incorrect. While the concern about inadequate washout is correct, the calculation is wrong. Five half-lives of norfluoxetine (not three) is the standard used to determine clearance to sub-pharmacological concentrations, yielding approximately five weeks -- not four.
Option E: Option E is incorrect. Statins are not CYP2D6 inhibitors in a clinically meaningful sense and do not impair phenelzine metabolism. This option describes a non-existent drug interaction.
6. A 53-year-old man with recurrent major depressive disorder has been on nortriptyline for 16 weeks. He was titrated from 50 mg to 75 mg nightly at week 8 after a partial response, with a plasma level of 108 ng/mL at that point. At week 12, with the level at 108 ng/mL and only partial improvement, his psychiatrist increased the dose further to 100 mg nightly. At week 16 his plasma level is 198 ng/mL and his depression rating scores are significantly worse than at week 12. He reports no new medications, no medical illness, and no psychosocial stressors. His psychiatrist is puzzled and considers increasing the dose to 125 mg. Which of the following represents the correct interpretation of this clinical picture and the appropriate next step?
A) The worsening at week 16 represents treatment-emergent bipolar disorder unmasked by nortriptyline; the appropriate next step is to discontinue nortriptyline, obtain a detailed family history for bipolar disorder, and initiate a mood stabilizer; plasma levels above 150 ng/mL are known to trigger manic switching in patients with unrecognized bipolar diathesis
B) The worsening reflects inadequate dosing; the plasma level of 198 ng/mL is still below the toxicity threshold of 500 ng/mL and dose escalation to 125 mg nightly is appropriate; the therapeutic range of 50 to 150 ng/mL is a conservative estimate derived from older studies and modern practice supports targeting levels up to 250 ng/mL for treatment-resistant cases
C) The plasma level of 198 ng/mL has exceeded the upper boundary of nortriptyline's therapeutic window (50 to 150 ng/mL), and the clinical worsening is the expected pharmacodynamic consequence of the curvilinear (inverted-U) concentration-response relationship; the appropriate next step is to reduce the dose back toward 75 mg nightly and recheck the plasma level, targeting a concentration in the 80 to 130 ng/mL range where optimal antidepressant efficacy has been demonstrated
D) The worsening at week 16 reflects CYP2D6 autoinduction triggered by the dose increase from 75 to 100 mg; at higher nortriptyline doses the drug accelerates its own metabolism, paradoxically lowering the free fraction available for receptor binding despite an elevated total plasma concentration; the appropriate next step is to add a low-dose CYP2D6 inhibitor to restore the therapeutic free fraction
E) The worsening reflects serotonin receptor downregulation after 16 weeks of nortriptyline-induced SERT inhibition; plasma level monitoring is not relevant to this pharmacodynamic tolerance process; the appropriate next step is to add a low-dose SSRI to counteract the receptor downregulation through a complementary serotonergic mechanism
ANSWER: C
Rationale:
Option C is correct. Nortriptyline has a well-characterized curvilinear -- inverted-U shaped -- plasma concentration-response relationship with a therapeutic window of 50 to 150 ng/mL. Antidepressant efficacy increases as plasma concentrations rise toward the mid-range of the window and then decreases at concentrations above 150 ng/mL. A plasma level of 198 ng/mL exceeds the upper boundary of the therapeutic window, and the clinical deterioration observed -- worsening depression scores despite higher plasma concentration -- is the predicted pharmacodynamic consequence of this relationship. The psychiatrist's instinct to increase the dose further to 125 mg is precisely wrong: it would drive the plasma level even higher into the supratherapeutic range and worsen the clinical outcome further. The correct action is to reduce the dose back toward 75 mg nightly and recheck the level at steady state, targeting the mid-therapeutic range of approximately 80 to 130 ng/mL where efficacy was documented and approaching its optimum. This is the scenario in which nortriptyline's plasma level monitoring provides its most direct and actionable clinical value -- not merely detecting toxicity, but guiding dose reduction to restore efficacy.
Option A: Option A is incorrect. While antidepressants can occasionally unmask bipolar disorder, this presentation is temporally linked to the dose increase and level elevation, pointing directly to the curvilinear pharmacodynamic relationship. There is no established pharmacological mechanism by which nortriptyline levels above 150 ng/mL specifically trigger manic switching.
Option B: Option B is incorrect. The therapeutic window of 50 to 150 ng/mL for nortriptyline is based on extensive evidence including placebo-controlled trials demonstrating the curvilinear relationship; it is not a conservative historical estimate. Further dose escalation in a patient already above 150 ng/mL with worsening symptoms is contraindicated.
Option D: Option D is incorrect. Nortriptyline does not induce its own CYP2D6 metabolism. CYP2D6 autoinduction by nortriptyline is not a recognized pharmacological phenomenon.
Option E: Option E is incorrect. The worsening is not attributable to serotonin receptor downregulation, and the temporal correlation with the dose increase and level elevation makes a pharmacokinetic-pharmacodynamic explanation far more parsimonious. Adding an SSRI to a patient already above the therapeutic window would compound the problem.
7. A 58-year-old man on phenelzine 60 mg daily for treatment-resistant depression is scheduled for elective inguinal hernia repair under general anesthesia. During the preoperative evaluation the anesthesiologist plans to use meperidine for intraoperative and postoperative analgesia. The patient's psychiatrist is called and strongly objects to this plan. Which of the following correctly identifies why meperidine is contraindicated in this patient, the clinical syndrome that would result from this combination, and a safe opioid alternative?
A) Meperidine is contraindicated because it inhibits the serotonin transporter (SERT) in addition to its mu-opioid receptor agonism; combined SERT inhibition and irreversible MAO-A inhibition by phenelzine prevents both serotonin reuptake and serotonin catabolism, producing life-threatening serotonin syndrome characterized by hyperthermia, agitation, muscle rigidity, and hemodynamic instability; morphine is a substantially safer alternative because it lacks clinically significant SERT inhibitory activity and does not displace norepinephrine from adrenergic nerve terminals
B) Meperidine is contraindicated because it is an MAO-A substrate that accumulates to toxic plasma concentrations when MAO-A is irreversibly inhibited by phenelzine; the resulting meperidine toxicity manifests as opioid excess with respiratory depression, miosis, and bradycardia requiring naloxone reversal; fentanyl is contraindicated for the same reason; tramadol is the only safe opioid because it is eliminated by renal excretion without MAO-A involvement
C) Meperidine is contraindicated because its active metabolite normeperidine is a selective MAO-B inhibitor that competitively amplifies phenelzine's effect; the resulting enhanced MAO inhibition produces excessive norepinephrine accumulation and a hypertensive crisis identical to the tyramine pressor response; hydromorphone is the safe alternative because it lacks normeperidine formation
D) Meperidine is contraindicated because it inhibits catechol-O-methyltransferase (COMT), the enzyme responsible for norepinephrine catabolism at peripheral sympathetic terminals; combined COMT inhibition and MAO-A inhibition completely abolishes norepinephrine catabolism, producing a sustained hypertensive crisis lasting 24 to 48 hours; remifentanil is the safe alternative because of its rapid esterase-mediated metabolism
E) Meperidine is contraindicated because phenelzine inhibits CYP3A4, the primary enzyme responsible for meperidine conversion to normeperidine; normeperidine accumulation from impaired conversion produces seizures that are refractory to standard anticonvulsants; codeine is the safe alternative because it does not undergo CYP3A4-mediated metabolism
ANSWER: A
Rationale:
Option A is correct. Meperidine is absolutely contraindicated in patients on irreversible MAOIs including phenelzine. Unlike most opioids, meperidine has significant serotonin reuptake inhibitory (SERT-blocking) properties in addition to its mu-opioid receptor agonism. When meperidine is administered to a patient whose MAO-A is irreversibly inhibited, the combination simultaneously blocks both of serotonin's primary clearance mechanisms: SERT inhibition prevents serotonin reuptake from the synapse, and MAO-A inhibition prevents intraneuronal serotonin catabolism. The resulting massive serotonin accumulation produces serotonin syndrome -- a potentially fatal reaction characterized by hyperthermia, agitation, muscle rigidity (distinguishing it from opioid toxicity), diaphoresis, and hemodynamic instability. Morphine is a substantially safer opioid alternative because it lacks clinically significant SERT inhibitory activity and does not act as an indirect sympathomimetic at adrenergic nerve terminals. Fentanyl and hydromorphone are also considered safer alternatives for the same reason. The anesthesiologist should be advised to substitute morphine or fentanyl for meperidine and to have phenelzine interaction precautions clearly documented in the perioperative record.
Option B: Option B is incorrect. Meperidine is not an MAO-A substrate that accumulates through impaired metabolism, and tramadol is not safe with MAOIs -- tramadol itself inhibits SERT and carries serotonin syndrome risk with irreversible MAOIs.
Option C: Option C is incorrect. Normeperidine is not an MAO-B inhibitor. This mechanism is fabricated.
Option D: Option D is incorrect. Meperidine does not inhibit COMT. The proposed mechanism is pharmacologically implausible, and remifentanil is metabolized by plasma esterases, not by MAO or COMT.
Option E: Option E is incorrect. Phenelzine does not inhibit CYP3A4 in a clinically meaningful way. The normeperidine accumulation-seizure mechanism described applies to high cumulative doses of meperidine in patients with renal impairment -- it is not the relevant interaction here. Codeine is not a safe MAOI alternative and carries its own serotonergic risks.
8. A 38-year-old woman presents to a psychiatry clinic with a two-year history of depression. She reports that her mood brightens noticeably when something good happens -- a compliment from her boss, a pleasant phone call -- but returns to a depressed baseline within hours. She sleeps 12 to 14 hours on weekends and still feels unrefreshed. She has gained 22 pounds over two years with intense cravings for carbohydrates and sweets. She describes her arms and legs as feeling like "they are filled with concrete," making it hard to exercise even when motivated. She experiences extreme distress when she perceives any hint of rejection in her relationships, which has caused significant occupational and interpersonal impairment. She has completed two adequate SSRI trials (sertraline 200 mg for 10 weeks and escitalopram 20 mg for 10 weeks) without meaningful response. Which of the following represents the most evidence-supported pharmacological next step for this specific presentation?
A) Augment with lithium added to escitalopram; lithium augmentation has the strongest evidence base for treatment-resistant unipolar depression and directly targets the serotonergic deficit underlying mood reactivity and rejection sensitivity through its effects on second messenger systems
B) Switch to venlafaxine at high dose (225 mg daily); the noradrenergic component of SNRI activity specifically targets the leaden paralysis and hypersomnia features of this presentation, and multiple randomized trials have demonstrated SNRI superiority over SSRIs in the atypical depression subtype defined by these features
C) Switch to mirtazapine; its combined alpha-2 autoreceptor blockade and H1 antihistaminic properties increase noradrenergic and serotonergic tone while producing sedation and appetite stimulation that therapeutically address the hypersomnia and hyperphagia in atypical depression
D) Switch to bupropion; the dopaminergic and noradrenergic mechanism of bupropion specifically targets the anhedonia, leaden paralysis, and hypersomnia features of atypical depression, and the absence of serotonergic activity avoids the SERT-mediated receptor desensitization that produced tolerance in the prior SSRI trials
E) Initiate an MAOI such as phenelzine after appropriate SSRI washout; MAOIs have demonstrated superiority over both TCAs and placebo in randomized controlled trials specifically in atypical depression as defined by the features this patient exhibits -- mood reactivity, hypersomnia, hyperphagia, leaden paralysis, and rejection sensitivity -- and represent the most robustly evidence-supported pharmacological treatment for this specific subtype in patients who have failed SSRI therapy
ANSWER: E
Rationale:
Option E is correct. This patient's clinical presentation precisely defines the atypical depression subtype: mood reactivity (brightening with positive events), hypersomnia, hyperphagia with carbohydrate craving, leaden paralysis, and rejection sensitivity causing functional impairment. This is not simply treatment-resistant depression -- it is a specific phenomenological subtype for which the evidence base is subtype-specific. Multiple randomized controlled trials, most notably those conducted by Liebowitz and colleagues, have demonstrated phenelzine's superiority over imipramine and over placebo specifically in patients meeting criteria for atypical depression defined by these features. This evidence base, which has been replicated, makes MAOIs the most robustly supported pharmacological treatment for this specific subtype. After an appropriate washout from escitalopram (approximately one to two weeks), phenelzine can be initiated with appropriate dietary counseling and drug interaction education. The patient's prior SSRI failures, combined with the full atypical depression phenotype, make this a strong indication for MAOI consideration.
Option A: Option A is incorrect. Lithium augmentation has the strongest evidence for treatment-resistant unipolar depression broadly but has not demonstrated superiority specifically in the atypical depression subtype defined by mood reactivity and the other features present.
Option B: Option B is incorrect. SNRIs have not demonstrated superiority over SSRIs specifically in the atypical depression subtype in adequately powered randomized trials. The mechanistic rationale for noradrenergic targeting is plausible but does not constitute the trial evidence that establishes MAOI primacy.
Option C: Option C is incorrect. Mirtazapine's properties are mechanistically appealing for some features of this presentation but it lacks the subtype-specific randomized trial evidence supporting MAOIs in atypical depression.
Option D: Option D is incorrect. Bupropion has not demonstrated superiority over SSRIs in head-to-head randomized trials specifically in the atypical depression subtype. The mechanism-based rationale does not substitute for subtype-specific clinical trial evidence.
9. A 31-year-old man with suspected amitriptyline overdose has been in the emergency department for 90 minutes. His QRS is 122 ms and he has received two bolus doses of sodium bicarbonate with modest QRS narrowing to 114 ms. He suddenly develops a generalized tonic-clonic seizure. The nurse asks the physician for an anticonvulsant order. The physician orders lorazepam 2 mg intravenously and simultaneously gives the nurse an explicit instruction about a second anticonvulsant agent. Which of the following represents the physician's correct anticonvulsant order and correct explicit instruction, with the mechanistic reasoning for both?
A) Order lorazepam 2 mg IV and instruct the nurse to prepare phenytoin 20 mg/kg IV as the second-line agent if lorazepam fails; phenytoin is the preferred second-line anticonvulsant in TCA overdose because its sodium channel-stabilizing properties directly counteract the TCA-induced depolarization block in the CNS that is producing the seizure activity
B) Order lorazepam 2 mg IV and instruct the nurse that phenytoin and fosphenytoin are absolutely contraindicated in this patient; lorazepam acts at GABA-A receptors to increase inhibitory chloride conductance and does not affect cardiac conduction; phenytoin's sodium channel-blocking mechanism, which is the basis of its anticonvulsant effect, is directly additive with the TCA-induced cardiac sodium channel blockade already present, and administering phenytoin risks worsening QRS prolongation and precipitating ventricular arrhythmia in an already compromised myocardium
C) Order lorazepam 2 mg IV and instruct the nurse to prepare physostigmine as the second agent if seizures recur; physostigmine will reverse the central anticholinergic component driving seizure susceptibility, complementing lorazepam's GABAergic effect; phenytoin is safe in this setting because TCA-induced sodium channel blockade is specific to cardiac channels (Nav1.5) and does not interact with the CNS sodium channels (Nav1.2) that phenytoin targets
D) Order levetiracetam 1,500 mg IV as the first-line agent rather than lorazepam; levetiracetam has no effect on cardiac conduction and is therefore preferred over benzodiazepines, which depress cardiac contractility and can cause hypotension in an already hemodynamically unstable patient; phenytoin should be added simultaneously as a second agent given the severity of the TCA toxicity
E) Order diazepam 10 mg IV and instruct the nurse that lorazepam is contraindicated in TCA overdose because its propylene glycol vehicle produces lactic acidosis that worsens the already low blood pH from cardiac compromise; phenytoin should be prepared as the definitive anticonvulsant while diazepam provides brief seizure suppression
ANSWER: B
Rationale:
Option B is correct. This scenario requires both a correct anticonvulsant choice and explicit contraindication of the most dangerous alternative. Lorazepam (or diazepam) intravenously is the correct first-line anticonvulsant for TCA-associated seizures. Benzodiazepines enhance GABAergic inhibitory conductance at GABA-A receptors, raising the seizure threshold without any effect on cardiac sodium channels or cardiac conduction. The explicit contraindication the physician must give is against phenytoin and fosphenytoin. Phenytoin's primary anticonvulsant mechanism operates through sodium channel blockade -- it reduces the rate of recovery of voltage-gated sodium channels from inactivation. In a patient with TCA-induced cardiac sodium channel blockade already producing a QRS of 114 ms, adding a second sodium channel blocker is directly additive at the myocardium: it can worsen QRS prolongation further and precipitate ventricular tachycardia or ventricular fibrillation. This is a well-established and critically important contraindication in TCA toxicology, and reflex use of phenytoin as a "second-line anticonvulsant" without recognizing this context is a potentially fatal error.
Option A: Option A is incorrect. Phenytoin is the drug that must be avoided, not the backup choice. Its sodium channel-blocking mechanism is precisely what makes it dangerous in this setting -- it does not counteract TCA depolarization block, it compounds TCA cardiac sodium channel toxicity.
Option C: Option C is incorrect. Physostigmine is contraindicated in TCA overdose with cardiac sodium channel toxicity; its vagal effects risk bradycardia and asystole. The claim that phenytoin is safe because TCA sodium channel blockade is specific to Nav1.5 (cardiac) versus Nav1.2 (CNS) is incorrect -- phenytoin affects Nav1.5 in the myocardium and its administration in this context worsens cardiac toxicity regardless of its CNS channel target.
Option D: Option D is incorrect. Lorazepam does not depress cardiac contractility at standard doses in a clinically relevant way and is not contraindicated in TCA overdose. Levetiracetam is not established as first-line over benzodiazepines in this setting. Phenytoin should not be added simultaneously -- it must be avoided.
Option E: Option E is incorrect. Lorazepam is not contraindicated in TCA overdose; the propylene glycol concern applies only at very high cumulative doses over extended infusion periods, not to a single 2 mg dose. Diazepam is also acceptable, but the explicit prohibition of phenytoin is the critical instruction that must accompany the anticonvulsant order.
10. A 45-year-old man on tranylcypromine 30 mg twice daily for treatment-resistant depression develops an upper respiratory infection. He calls his psychiatrist's office asking whether he can take an over-the-counter cold preparation. The nurse reviews the label and notes it contains pseudoephedrine 30 mg and dextromethorphan 15 mg per dose. The psychiatrist advises the patient that both active ingredients are contraindicated with his medication and explains that each poses a distinct type of risk through a different mechanism. Which of the following correctly identifies the contraindication for each ingredient and its mechanistic basis?
A) Pseudoephedrine is contraindicated because it is metabolized by MAO-A to a toxic aldehyde intermediate that accumulates when MAO-A is inhibited, producing hepatotoxicity; dextromethorphan is contraindicated because it competes with tranylcypromine for MAO-B binding sites, reducing the antidepressant effect of tranylcypromine through competitive pharmacodynamic antagonism
B) Pseudoephedrine is contraindicated because it is a direct alpha-1 adrenergic agonist whose vasopressor effect is prolonged when MAO-A is inhibited due to impaired catecholamine catabolism at the receptor; dextromethorphan is contraindicated because it is a potent MAO-A inhibitor that would produce additive non-selective MAO inhibition with tranylcypromine, multiplying the dietary tyramine interaction risk
C) Pseudoephedrine is contraindicated because tranylcypromine inhibits CYP2D6, the primary enzyme for pseudoephedrine metabolism, causing pseudoephedrine to accumulate to toxic concentrations; dextromethorphan is contraindicated because it is a dopamine precursor that is converted to dopamine by aromatic amino acid decarboxylase when MAO-A-mediated catabolism is blocked
D) Pseudoephedrine is contraindicated because it is an indirect sympathomimetic that releases norepinephrine from adrenergic nerve terminals; when MAO-A (and MAO-B) are irreversibly inhibited by tranylcypromine, sympathetic nerve terminals contain greatly increased stores of norepinephrine available for displacement, amplifying the pressor response to any indirect sympathomimetic and risking hypertensive crisis; dextromethorphan is contraindicated because it inhibits serotonin reuptake through SERT, and combined SERT inhibition with MAO-A inhibition risks serotonin syndrome
E) Both pseudoephedrine and dextromethorphan are contraindicated through the same mechanism: both are MAO-A substrates that accumulate when MAO-A is inhibited, and both produce serotonin syndrome through substrate accumulation; the clinical presentations would be identical for either agent taken alone with tranylcypromine
ANSWER: D
Rationale:
Option D is correct. The two components pose distinct and pharmacologically well-characterized risks. Pseudoephedrine is an indirect sympathomimetic: it enters adrenergic nerve terminals via the norepinephrine transporter and displaces stored norepinephrine into the synapse -- the same mechanism as tyramine. When tranylcypromine irreversibly inhibits both MAO-A and MAO-B, intraneuronal norepinephrine is not catabolized between release events and accumulates to higher concentrations in storage vesicles. Any indirect sympathomimetic taken in this context displaces a disproportionately large norepinephrine load, greatly amplifying the pressor response and risking hypertensive crisis comparable to the dietary tyramine reaction. Dextromethorphan is a common antitussive that inhibits SERT in addition to its NMDA receptor and sigma-1 receptor activity. Combined SERT inhibition with tranylcypromine's irreversible MAO-A inhibition prevents both serotonin reuptake and serotonin catabolism simultaneously, risking serotonin syndrome -- the same mechanism responsible for the absolute meperidine-MAOI contraindication. The patient needs to understand that these two risks are mechanistically different: one is a noradrenergic hypertensive crisis risk (pseudoephedrine) and one is a serotonergic syndrome risk (dextromethorphan). All over-the-counter cold preparations must be screened carefully by MAOI-treated patients.
Option A: Option A is incorrect. Pseudoephedrine is not a MAO-A substrate that produces a toxic aldehyde; it is an indirect sympathomimetic. Dextromethorphan does not compete with tranylcypromine for MAO binding sites.
Option B: Option B is incorrect. Pseudoephedrine is not a direct alpha-1 agonist; it is an indirect sympathomimetic. Dextromethorphan is not a MAO-A inhibitor.
Option C: Option C is incorrect. Tranylcypromine does not inhibit CYP2D6 in a clinically meaningful way. Dextromethorphan is not a dopamine precursor.
Option E: Option E is incorrect. Pseudoephedrine and dextromethorphan pose distinct risks through different mechanisms -- noradrenergic versus serotonergic. They are not both MAO-A substrates, and their clinical presentations would not be identical.
11. A 44-year-old woman on phenelzine 45 mg daily is being switched to venlafaxine after a change in her insurance coverage makes phenelzine impractical to obtain. Her psychiatrist stops the phenelzine and plans to start venlafaxine. A resident on the team asks two questions: (1) how long must the patient wait after stopping phenelzine before venlafaxine can be started, and (2) if venlafaxine eventually fails and the patient needs to return to an MAOI in the future, how long must she wait after stopping venlafaxine before starting an MAOI? The psychiatrist gives both answers with the correct pharmacokinetic rationale for each. Which of the following correctly states both washout intervals and the distinct pharmacokinetic determinant for each?
A) After stopping phenelzine, the patient must wait two weeks before starting venlafaxine; this interval is determined by the time required for MAO enzyme resynthesis after irreversible covalent inactivation -- phenelzine's plasma half-life is only 1.5 to 3 hours, but MAO activity cannot recover until new enzyme protein is synthesized; if venlafaxine is subsequently stopped before restarting an MAOI in the future, approximately one week washout is required, determined by plasma clearance of venlafaxine and its active metabolite desvenlafaxine to sub-pharmacological concentrations at five half-lives of the longer-lived species
B) After stopping phenelzine, the patient must wait five weeks before starting venlafaxine; this interval reflects the time required for phenelzine's active metabolite phenylethylhydrazine to clear completely; if venlafaxine is subsequently stopped, two weeks is required before starting an MAOI because venlafaxine irreversibly inhibits SERT and transporter resynthesis takes two weeks
C) After stopping phenelzine, the patient must wait one week before starting venlafaxine; this interval is based on five half-lives of phenelzine (half-life approximately 1.5 to 3 hours, five half-lives approximately 15 hours, rounded to one week for clinical safety); if venlafaxine is subsequently stopped, five weeks washout is required before starting an MAOI because desvenlafaxine has a half-life of approximately one week
D) After stopping phenelzine, the patient must wait two weeks before starting venlafaxine; this interval is the same as required when stopping any antidepressant before starting an MAOI, because all antidepressants suppress MAO-A gene expression and two weeks is required for transcriptional recovery; if venlafaxine is subsequently stopped, two weeks is also required because venlafaxine's noradrenergic activity creates a sustained withdrawal state that sensitizes the MAO system
E) After stopping phenelzine, the patient must wait four weeks before starting venlafaxine; phenelzine is hepatically acetylated and slow acetylators retain pharmacologically active acetyl-phenelzine for up to four weeks; if venlafaxine is subsequently stopped, three weeks washout is required because desvenlafaxine has a half-life of approximately four days and three weeks approximates five half-lives
ANSWER: A
Rationale:
Option A is correct. The two washout intervals are governed by different pharmacokinetic and pharmacodynamic determinants. After stopping phenelzine, the required washout before starting venlafaxine is two weeks. This interval is not derived from phenelzine's plasma half-life (approximately 1.5 to 3 hours -- the drug is pharmacokinetically cleared within a day) but from the time required for MAO enzyme resynthesis after irreversible covalent inactivation of MAO by phenelzine. Phenelzine forms a covalent bond with the FAD cofactor of MAO, permanently inactivating the enzyme. MAO activity can only recover through synthesis of new enzyme protein, which takes approximately two weeks. Until sufficient new MAO is synthesized, systemic serotonin cannot be adequately catabolized, and any serotonergic drug risks serotonin syndrome. The second washout -- after stopping venlafaxine before a future MAOI -- is approximately one week, determined by plasma pharmacokinetics: venlafaxine has a half-life of approximately five hours and its active metabolite desvenlafaxine has a half-life of approximately eleven hours. Five half-lives of desvenlafaxine clears within approximately two to three days, and the clinical washout convention is approximately one week. This is shorter than the fluoxetine washout (five weeks) precisely because desvenlafaxine's half-life is much shorter than norfluoxetine's. The asymmetry between these two calculations -- pharmacodynamic enzyme resynthesis in the MAOI-stop direction, pharmacokinetic plasma clearance in the SNRI-stop direction -- is a core concept in antidepressant sequencing.
Option B: Option B is incorrect. The phenelzine washout is two weeks, not five weeks; phenylethylhydrazine is not a long-lived active metabolite governing the washout. Venlafaxine is a reversible SERT inhibitor -- no transporter resynthesis is required.
Option C: Option C is incorrect. Rounding phenelzine's plasma half-life to a one-week washout ignores the enzyme resynthesis requirement entirely -- the plasma half-life is irrelevant to the washout calculation for an irreversible inhibitor. Desvenlafaxine does not have a one-week half-life; it is approximately eleven hours.
Option D: Option D is incorrect. Antidepressants do not suppress MAO-A gene expression; the two-week phenelzine washout reflects covalent enzyme inactivation and resynthesis, not transcriptional suppression. The venlafaxine washout is approximately one week, not two weeks.
Option E: Option E is incorrect. The phenelzine washout is not four weeks and is not governed by acetylation status in a way that extends the washout beyond two weeks. Desvenlafaxine's half-life is approximately eleven hours, not four days; the washout calculation accordingly yields approximately one week, not three weeks.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.